Help us: Donate
Follow us on:
×

Menu

Back

DNA Testing Company Veritas Genetics Suspends U.S. Operations

sudden downtrendsudden downtrend
 

After experiencing financial issues, DNA testing company Veritas Genetics has announced the suspension of its U.S. operations in an unexpected announcement on December 4th 2019.

The company is perhaps best known for being co-founded by renowned Harvard University geneticist George Church and has been working towards reducing the costs of genome sequencing so that it could become widely available. There are other companies offering genome sequencing, such as 23andMe, but they only look at a small portion of the total DNA; Veritas, on the other hand, sequences the entire genome for $599.

According to Crunchbase, the company had raised over $50 million in venture funding, but that money appears to have run out. Veritas recently took to Twitter and stated that it had encountered “an unexpected adverse financing situation” that has led to the closure of its U.S. operations.

Allegedly, the closure may be linked in part to investors’ concerns over Chinese investment in the company and the current administration’s moves to prevent Chinese investment in U.S. companies. Veritas’s China-based investors include Lilly Asia Ventures, TrustBridge Partners, and Simcere Pharmaceutical.

The closure sees a total of around 50 members of staff being terminated in Danvers, Massachusetts. While this is a blow for the company, it will continue to operate in China, Latin America, and Europe and has vowed to continue its mission of driving down the cost of genome sequencing.

Conclusion

Hopefully, with more companies becoming involved in genome sequencing and its move towards becoming a more commonly used diagnostic tool in healthcare, we will see the prices of whole genome sequencing tumble in the next decade to become widely accessible and affordable. While this is disappointing news for people interested in sequencing their DNA, it does not necessarily mean the end of the line for Veritas, which will be continuing to operate in regions more conducive to their business.

HELP SPREAD THE WORD
Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension:
Lifespan.io YouTube
Lifespan.io Facebook
Lifespan.io Twitter
Lifespan.io Instagram
Lifespan.io Instagram
Lifespan.io Discord
Thank You!

CategoryNews
About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.